Cargando…

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

INTRODUCTION: Despite advances in treating high-risk neuroblastoma, 50-60% of patients still suffer relapse, necessitating new treatment options. Bispecific trifunctional antibodies (trAbs) are a promising new class of immunotherapy. TrAbs are heterodimeric IgG-like molecules that bind CD3 and a tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivasko, Sara Marie, Anders, Kathleen, Grunewald, Laura, Launspach, Michael, Klaus, Anika, Schwiebert, Silke, Ruf, Peter, Lindhofer, Horst, Lode, Holger N., Andersch, Lena, Schulte, Johannes H., Eggert, Angelika, Hundsdoerfer, Patrick, Künkele, Annette, Zirngibl, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869131/ https://www.ncbi.nlm.nih.gov/pubmed/36700232 http://dx.doi.org/10.3389/fimmu.2022.1023206

Ejemplares similares

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
por: Ruf, Peter, et al.
Publicado: (2012)

Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis
por: Sulejmani, Ornela, et al.
Publicado: (2021)

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis
por: Ströhlein, Michael A, et al.
Publicado: (2009)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
por: Ruf, Peter, et al.
Publicado: (2021)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
por: Grunewald, Laura, et al.
Publicado: (2021)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017)

Expansion microscopy with carboxylic trifunctional linkers: Expansion microscopy with carboxylic trifunctional linkers
por: Chen, Xuecheng, et al.
Publicado: (2022)

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
por: Textor, Ana, et al.
Publicado: (2021)

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022)

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models
por: Labrijn, Aran F., et al.
Publicado: (2017)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
por: Buhmann, Raymund, et al.
Publicado: (2013)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement
por: Jia, Leili, et al.
Publicado: (2010)

Immunization with HIV protease peptides linked to syngeneic erythrocytes
por: Boberg, Andreas, et al.
Publicado: (2007)

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4(+) CAR T Cell Efficacy
por: Ali, Solin, et al.
Publicado: (2020)

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010)

Tumor Targeting, Trifunctional Dendritic Wedge
por: Dubey, Ramin, et al.
Publicado: (2014)

Failure of suckling to transfer immunity to a syngeneic rat sarcoma.
por: Eccles, S. A., et al.
Publicado: (1978)

Enhanced Growth of Syngeneic Moloney Sarcoma with Decreased Immunity in the Regressors
por: Mayer, A. M. S., et al.
Publicado: (1977)

IMMUNE AND NATURAL ANTIBODIES TO SYNGENEIC MURINE PLASMA CELL TUMORS
por: Herberman, Ronald B., et al.
Publicado: (1972)

Syngeneic monoclonal antiidiotype can induce cellular immunity to reovirus
Publicado: (1984)

Decidual-Placental Immune Landscape During Syngeneic Murine Pregnancy
por: Li, Yan, et al.
Publicado: (2018)

Characterization of immune cell populations in syngeneic murine tumor models
por: Snipstad, Sofie, et al.
Publicado: (2023)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Synthesis of trifunctional cyclo-β-tripeptide templates
por: Stein, Frank, et al.
Publicado: (2012)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models
por: Wang, Feng, et al.
Publicado: (2019)

Experimental systemic amyloidosis induced by immunization with syngeneic organ extracts in mice
Publicado: (1986)

Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
por: Khalsa, Jasneet Kaur, et al.
Publicado: (2021)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
por: Wu, Zhiyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s12svrkubm8nr4vpef72omslb4